Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cangen Biotechnologies and Olympus Corporation have expanded their research collaboration and will now move development of a DNA and protein based diagnostic test for the early detection of lung cancer into the clinical phase.
Subscribe to our email newsletter
Cangen has commenced patient recruitment for a study at clinical sites in Asia and will receive funding from Olympus in support of the study and ongoing research and clinical development efforts. Cangen will manage the study from its Asia clinical trial center in Seoul, Korea.
Cangen has identified several key DNA markers that exhibit 70-80% accuracy in the detection of lung cancer. The company aims to use these DNA markers alongside protein-based markers to improve sensitivity and specificity. Olympus and Cangen are aiming for FDA approval after approximately two years.
“With our partners at Olympus, we have made dramatic progress over the last six months in the development of the test and platform for the early detection of lung cancer,” stated Dr Chul So Moon, CEO of Cangen Biotechnologies. “This additional commitment by Olympus to support the clinical development of our lung cancer detection technology underscores the viability of the technology as a key tool in saving human life.”